By SaiyanMed Research Team · Updated 5 November 2026 · For in-vitro research use only
RESEARCH USE ONLY — PROFESSIONAL LABORATORY USE. This article is for qualified laboratory personnel carrying out in-vitro assays or institutionally approved laboratory animal studies. It is not a home-use, personal-use, human-use, or veterinary-use guide. The information below must not be used as an administration, formulation, reconstitution, or dosing plan. CagriSema is an investigational fixed-dose combination (cagrilintide + semaglutide) under development by Novo Nordisk. Clinical trial results are summarized here as published research / company IR data, not as medical advice. Regulatory review for weight management was underway as of Q3 2026 sponsor disclosures; that is not the same as an approved label you can use as a protocol. SaiyanMed does not list a CagriSema combination SKU on this page. Component educational and RUO references (e.g., cagrilintide) are linked separately.
Quick answer
CagriSema is Novo Nordisk’s investigational once-weekly fixed-dose combination of cagrilintide (a long-acting amylin receptor agonist / amylin analogue) and semaglutide (a long-acting GLP-1 receptor agonist). Sponsor materials describe the combination as pairing complementary pathways that can reduce hunger and calorie intake in clinical development settings [Novo REDEFINE 1 CA 99/2024; Novo US ADA 2026].
Two Phase 3 program families structure the public map:
| Program | Population focus (high-level) | Example trials cited below |
|---|---|---|
| REDEFINE | Overweight / obesity (± related endpoints) | REDEFINE 1 (NCT05567796); REDEFINE 9 (2026-09-21 topline) |
| REIMAGINE | Type 2 diabetes | REIMAGINE 1–3 (ADA 2026); REIMAGINE 2 headline (2026-02-02); REIMAGINE 5 vs tirzepatide 5 mg (2026-09-21) |
As of Novo’s Q3 2026 disclosures (4 November 2026), the company said it was preparing for a U.S. launch of CagriSema in early 2027, subject to regulatory approval, and the Q3 investor presentation listed an FDA regulatory decision expected in Q4 2026 for the obesity path, with a December 2025 NDA filing for weight management referenced in the September 2026 Capital Markets Day press [Novo Q3 2026; Q3 2026 presentation PDF; CMD 2026-09-21].
CagriSema is not: mono-cagrilintide or a DIY mix of two research powders; zenagamtide / amycretin (Novo’s unimolecular GLP-1/amylin peptide); EloraTZP (Lilly’s eloralintide + tirzepatide combination); retatrutide (GIP/GLP-1/glucagon triple agonist); or an approved consumer weight-loss product you can dose from this page.
Two components explained
Cagrilintide (amylin pathway)
Cagrilintide is Novo’s long-acting amylin analogue / amylin receptor agonist used as one half of CagriSema and also studied as monotherapy in some trial arms (e.g., REDEFINE 1; REIMAGINE 2) [REDEFINE 1 CA 99/2024; Novo US ADA 2026].
Deep mono reading on SaiyanMed: Cagrilintide educational hub · Cagrilintide RUO product (component reference material — not a CagriSema FDC vial) · Eloralintide vs Cagrilintide.
Semaglutide (GLP-1 pathway)
Semaglutide is a long-acting GLP-1 receptor agonist. Approved semaglutide products exist for labeled indications under their own brands and labels; CagriSema as a fixed-dose combination candidate remains a distinct investigational construct in the REDEFINE / REIMAGINE programs [Novo US ADA 2026; REIMAGINE 2 2026-02-02].
How the combination is labeled in development
| Label | Meaning in public records |
|---|---|
| CagriSema | Novo name for the cagrilintide + semaglutide fixed-dose combination program |
| FDC / fixed-dose combination | Sponsor language for co-presented strengths (e.g., “2.4 mg / 2.4 mg”, “1.0 mg / 1.0 mg”) as trial / IR dose concepts — not lab mixing recipes |
| REDEFINE | Phase 3 obesity / overweight program family |
| REIMAGINE | Phase 3 type 2 diabetes program family |
Practical lab tip: do not treat a vial labelled “cagrilintide” plus a separate semaglutide lot as chemically or clinically equivalent to Novo’s clinical-trial CagriSema drug product. Combination identity is a manufacturing/regulatory construct, not a DIY mix.
REDEFINE obesity program
Every design and outcome figure below is as publicly reported by Novo IR / company announcements or ClinicalTrials.gov. None of it is a reconstitution recipe, titration schedule for laboratory use, or eligibility advice for personal enrollment. Milligram figures are trial-reported dose labels.
REDEFINE 1 — pivotal obesity topline (Company announcement No 99 / 2024)
REDEFINE 1 was a 68-week efficacy and safety Phase 3 trial of once-weekly subcutaneous CagriSema (described as a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) versus the individual components and placebo, all once-weekly. The trial randomised 3,417 people with obesity or overweight with one or more comorbidities and a mean baseline body weight of 106.9 kg [REDEFINE 1 CA 99/2024; NCT05567796].
Registry snapshot (ClinicalTrials.gov, fetch for this draft) [NCT05567796]:
| Field | Public value |
|---|---|
| Brief title | A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight |
| Status | ACTIVE_NOT_RECRUITING |
| Start | 2022-11-01 (actual) |
| Primary completion | 2024-10-30 (actual) |
| Enrollment (registry) | ~3400 estimated |
| Dual primary themes | Relative change in body weight (CagriSema vs placebo); proportion achieving ≥5% weight reduction |
Flexible-protocol note (sponsor): after 68 weeks, 57.3% of patients treated with CagriSema were on the highest dose, versus 82.5% with cagrilintide 2.4 mg and 70.2% with semaglutide 2.4 mg [REDEFINE 1 CA 99/2024].
Efficacy (trial product estimand) at week 68
Sponsor: “effects of treatment if all people adhered to treatment,” trial product estimand per protocol footnote [REDEFINE 1 CA 99/2024]:
| Arm (as labeled) | Mean body-weight change |
|---|---|
| CagriSema | −22.7% |
| Cagrilintide 2.4 mg | −11.8% |
| Semaglutide 2.4 mg | −16.1% |
| Placebo | −2.3% |
Proportion reaching ≥25% weight loss at week 68: 40.4% (CagriSema) vs 6.0% (cagrilintide), 16.2% (semaglutide), 0.9% (placebo) [REDEFINE 1 CA 99/2024].
Treatment policy estimand at week 68
| Arm | Mean body-weight change |
|---|---|
| CagriSema | −20.4% |
| Cagrilintide 2.4 mg | −11.5% |
| Semaglutide 2.4 mg | −14.9% |
| Placebo | −3.0% |
Safety (high-level, as reported): CagriSema, cagrilintide, and semaglutide “appeared to have a safe and well-tolerated profile”; most common adverse events with CagriSema were gastrointestinal, mostly mild to moderate and diminishing over time, consistent with the GLP-1 RA class [REDEFINE 1 CA 99/2024].
NEJM pointer: REDEFINE 1 is indexed to NEJM DOI 10.1056/nejmoa2502081. Full-text HTML/PDF was not successfully fetched for this draft (paywall / bot block); figures above are from the Novo company announcement PDF, not a retyped NEJM table.
REDEFINE 9 — lower-dose obesity topline (2026-09-21)
At Capital Markets Day (21 September 2026), Novo reported REDEFINE 9 toplines: once-weekly CagriSema 1.0 mg / 1.0 mg versus placebo as adjunct to diet and exercise in adults with overweight or obesity. Primary endpoints included relative change in body weight and the proportion achieving ≥5% weight reduction at week 68. Sponsor headline: weight loss 21.0% with CagriSema 1.0/1.0 mg versus 2.0% with placebo (primary superiority met). The trial also investigated a 1.7 mg / 1.7 mg arm; open press used for this draft did not publish a complete numeric table for that arm or the ≥5% responder percentage — do not invent them [CMD 2026-09-21; Novo Q3 2026].
Q3 2026 presentation “next steps” for obesity also flags REDEFINE 11 and CagriSema HD planned readouts in H1 2027 and H1 2028 [Q3 2026 presentation PDF].
REIMAGINE T2D program
Program map (ADA 2026)
Novo’s U.S. ADA 2026 press framed REIMAGINE as Phase 3 CagriSema evaluation in adults with T2D across disease stages, with REIMAGINE 1–3 presented at ADA Scientific Sessions (New Orleans, 5–8 June 2026) and simultaneous journal publications noted for REIMAGINE 1–2 (Lancet Diabetes & Endocrinology) and REIMAGINE 3 (The Lancet) [Novo US ADA 2026].
| Trial | Duration | Population (high-level) | n (ADA / CT.gov) | Headline comparator theme |
|---|---|---|---|---|
| REIMAGINE 1 | 40 weeks | T2D inadequately controlled on diet/exercise | 189 | vs dose-matched placebo |
| REIMAGINE 2 | 68 weeks | T2D on metformin ± SGLT2i | 2,713 | vs semaglutide / cagrilintide / placebo |
| REIMAGINE 3 | 40 weeks | T2D add-on to basal insulin ± metformin | 274 | vs dose-matched placebo |
| REIMAGINE 5 | 60 weeks (topline) | T2D inadequately controlled on metformin, SGLT2i, or both | 1,023 (CT.gov actual) | vs tirzepatide 5 mg |
[Novo US ADA 2026; NCT06534411; CMD 2026-09-21]
ADA also notes that REIMAGINE 4 and REIMAGINE 5 evaluated CagriSema versus tirzepatide (2.4/2.4 and 1.0/1.0 concepts respectively). REIMAGINE 4 numeric toplines were not verified in primary IR for this draft — omit invented H2H percentages [Novo US ADA 2026].
REIMAGINE 1 — efficacy estimand (ADA table)
Baselines: mean HbA1c 7.8%; mean body weight 101.3 kg. Week 40 [Novo US ADA 2026]:
| Arm | HbA1c change | Body-weight change |
|---|---|---|
| CagriSema 2.4 / 2.4 mg (n=62) | −1.8% | −13.8% |
| CagriSema 1 / 1 mg (n=63) | −1.5% | −11.8% |
| Placebo pooled (n=64) | −0.1% | −1.4% |
(Treatment-regimen estimand values were nearly identical in the same press table.)
REIMAGINE 2 — efficacy estimand (ADA table)
Baselines: mean HbA1c 8.2%; mean body weight 100.9 kg. Week 68. Primary comparison theme: CagriSema 2.4/2.4 vs semaglutide 2.4 [Novo US ADA 2026; also REIMAGINE 2 2026-02-02]:
| Arm | HbA1c change | Body-weight change |
|---|---|---|
| CagriSema 2.4 / 2.4 mg (n=603) | −1.91% | −14.2% |
| Semaglutide 2.4 mg (n=605) | −1.75% | −10.2% |
| Cagrilintide 2.4 mg (n=152) | −0.80% | −8.4% |
| CagriSema 1 / 1 mg | −1.82% | −12.0% |
| Semaglutide 1 mg | −1.54% | −7.5% |
| Placebo (treatment-regimen, ADA) | −0.62% | −2.0% |
Treatment-regimen estimand (selected): CagriSema 2.4/2.4 −1.80% HbA1c / −12.9% weight vs semaglutide 2.4 −1.68% / −9.2% [Novo US ADA 2026].
GI AE frequencies (REIMAGINE 2, as reported): GI-related AEs in 67.2% (CagriSema 2.4/2.4) vs 53.9% (semaglutide 2.4) vs 39.5% (cagrilintide 2.4) vs 28.2% (placebo); AEs leading to discontinuation 8.5% vs 6.6% vs 4.6% vs 1.3% respectively [Novo US ADA 2026].
REIMAGINE 3 — efficacy estimand (ADA table)
Baselines: mean HbA1c 8.8%; mean body weight 88.2 kg. Week 40, add-on to basal insulin [Novo US ADA 2026]:
| Arm | HbA1c change | Body-weight change |
|---|---|---|
| CagriSema 2.4 / 2.4 mg (n=90) | −2.33% | −12.0% |
| CagriSema 1 / 1 mg | −2.10% | −10.4% |
| Placebo | −0.66% | +1.1% |
Recent public updates (REDEFINE 9 / REIMAGINE 5) and regulatory timing
REIMAGINE 5 vs tirzepatide 5 mg
21 September 2026 Capital Markets Day / press: in adults with type 2 diabetes inadequately controlled on metformin, an SGLT2 inhibitor, or both, CagriSema 1.0 mg / 1.0 mg achieved estimated average weight loss of 12.4% versus 9.1% with tirzepatide 5 mg at week 60 (superiority for weight), with HbA1c reduction 1.71% versus 1.67% (non-inferior) [CMD 2026-09-21; echoed in Novo Q3 2026].
Registry: NCT06534411 — completed; actual enrollment 1023 (fetch for this draft).
Label the comparison carefully: this is CagriSema 1.0/1.0 vs tirzepatide 5 mg at 60 weeks in the REIMAGINE 5 population — not a universal ranking against all tirzepatide strengths, all durations, or REDEFINE obesity populations. Cross-trial shopping of percentages is not a ranking.
Regulatory / launch language (sponsor, not a guarantee)
| Disclosure | What Novo said (as of cited date) |
|---|---|
| NDA (weight management) | Filed with FDA in December 2025 (CMD 2026-09-21 press) |
| FDA decision (obesity path) | Expected Q4 2026 (Q3 2026 presentation) |
| U.S. launch timing | Early 2027, subject to approval (CEO quote, Q3 2026 CA; presentation: “start of 2027”) |
| T2D path (presentation) | REDEFINE 3 CVOT readout expected H2 2027; T2D submission during H2 2027 with expected launch during 2028 (Q3 presentation narrative) |
[CMD 2026-09-21; Novo Q3 2026; Q3 2026 presentation PDF]
Sponsor launch preparation ≠ FDA approval ≠ RUO product availability.
vs tirzepatide (trial-reported comparisons only)
| Comparison | Source | Population / duration | Result (as reported) |
|---|---|---|---|
| CagriSema 1.0/1.0 vs tirzepatide 5 mg | REIMAGINE 5 topline 2026-09-21 + Q3 2026 echo | T2D on metformin ± SGLT2i; week 60 | Weight −12.4% vs −9.1% (superior); HbA1c −1.71% vs −1.67% (non-inferior) |
| CagriSema vs tirzepatide (other strengths / REIMAGINE 4) | ADA 2026 notes REIMAGINE 4 existed | — | No verified numeric topline in primary IR for this draft — do not invent |
Do not paste REDEFINE obesity percentages next to SURMOUNT / tirzepatide obesity labels as if they were the same trial. Estimands, baselines, dose concepts, and populations differ.
vs zenagamtide (combo vs unimolecular)
| Dimension | CagriSema | Zenagamtide (amycretin) |
|---|---|---|
| Architecture | Two APIs (cagrilintide + semaglutide FDC) | One dual peptide (GLP-1 + amylin in a single molecule) |
| Sponsor | Novo Nordisk | Novo Nordisk |
| Headline pathways | Amylin + GLP-1 | GLP-1 + amylin (unimolecular) |
| Late-stage map | REDEFINE / REIMAGINE Phase 3; obesity NDA filed Dec 2025 (sponsor) | AMAZE Phase 3 family (separate hub) |
| SaiyanMed SKU stance | No combo SKU on this page; link mono cagrilintide only | Educational hub first (see zenagamtide page) |
Same sponsor, different molecular strategies. Combining two RUO vials does not recreate either clinical product.
vs EloraTZP (different amylin + incretin pairing)
| Dimension | CagriSema | EloraTZP |
|---|---|---|
| Amylin component | Cagrilintide | Eloralintide |
| Incretin component | Semaglutide (GLP-1) | Tirzepatide (GIP + GLP-1) |
| Pathways (headline) | Amylin + GLP-1 | Amylin + GIP + GLP-1 |
| Sponsor | Novo | Lilly |
| Public late-stage shape | Multi-trial Phase 3 + obesity NDA timing disclosed | Ph2b separate injections → Ph3 co-formulation AMPLIFY |
Related mono compare: eloralintide vs cagrilintide. Also see what is retatrutide for a unimolecular GIP/GLP-1/glucagon contrast.
Research / analytical identity notes
Why “CagriSema” on a label is not identity
CagriSema denotes a sponsor fixed-dose combination program. A research catalog listing two separate lyophilized peptides does not prove equivalence to clinical-trial FDC drug product. Failure modes include wrong sequences, incomplete modification, isomer content, aggregation, incorrect ratios, or simple mislabeling.
Component vs combination
| Need | Appropriate SaiyanMed path |
|---|---|
| Mono-amylin analogue education + RUO tool | Cagrilintide hub · Product cagrilintide |
| Combination pipeline literacy | This hub only — no combo SKU claimed |
| Unimolecular GLP-1/amylin education | What is zenagamtide |
| Lilly amylin + tirzepatide combo literacy | What is EloraTZP |
| Triple-agonist education | What is retatrutide |
Handling themes (no recipes)
Lyophilized peptides are commonly stressed by moisture, heat, light, and repeated freeze–thaw after reconstitution. Follow the batch COA and your institution’s validated procedures. This article does not provide diluent volumes, concentrations, injection instructions, titration schedules, or study protocols.
Stock status on SaiyanMed
No CagriSema combination catalog SKU is claimed. Educational hub only. Related mono RUO tool: cagrilintide. Contact research support for notify-if-stock only after explicit go-ahead and COA review — do not assume combo inventory from this article.
Myth vs evidence
| Myth | Evidence-based correction |
|---|---|
| “CagriSema is just another name for cagrilintide.” | CagriSema is cagrilintide plus semaglutide as an FDC candidate [REDEFINE 1 CA 99/2024]. |
| “−22.7% is interchangeable with −21% and with REIMAGINE percentages.” | Different trials, dose concepts, populations, estimands, and durations (REDEFINE 1 vs REDEFINE 9 vs REIMAGINE). |
| “REIMAGINE 5 proves CagriSema beats all tirzepatide doses.” | Cited H2H is 1.0/1.0 vs tirzepatide 5 mg at 60 weeks in that T2D trial [CMD 2026-09-21]. |
| “Same as zenagamtide.” | Zenagamtide is unimolecular; CagriSema is two APIs [zenagamtide hub]. |
| “Same as EloraTZP.” | Different amylin analogue + different incretin partner (semaglutide vs tirzepatide) [EloraTZP hub]. |
| “Mix RUO cagrilintide + semaglutide powder = CagriSema.” | Not equivalent to clinical FDC; out of scope for RUO supply claims. |
| “Early-2027 launch language means I can dose it now.” | Sponsor preparation subject to approval ≠ approved use guide ≠ RUO protocol. |
| “RUO vials are for personal weight loss.” | Explicitly out of scope. |
Glossary
- CagriSema: Novo investigational fixed-dose combination of cagrilintide + semaglutide.
- Cagrilintide: Long-acting amylin analogue / amylin receptor agonist (mono and combo programs).
- Semaglutide: Long-acting GLP-1 receptor agonist (approved products exist under separate labels; combo remains investigational as CagriSema).
- REDEFINE: Phase 3 program family in overweight / obesity.
- REIMAGINE: Phase 3 program family in type 2 diabetes.
- Trial product / efficacy estimand: Effect under idealized adherence assumptions as defined in each sponsor footnote.
- Treatment policy / treatment-regimen estimand: Effect regardless of adherence / rescue as defined in each sponsor footnote.
- FDC: Fixed-dose combination (manufacturing/regulatory construct).
- RUO: Research Use Only — not for human or veterinary administration.
- COA: Certificate of Analysis for a specific lot.
FAQ
What is CagriSema?
CagriSema is Novo Nordisk’s investigational once-weekly fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 receptor agonist semaglutide, developed in the REDEFINE (obesity) and REIMAGINE (T2D) Phase 3 programs [REDEFINE 1 CA 99/2024; Novo US ADA 2026].
Is CagriSema the same as cagrilintide?
No. Cagrilintide is one component. CagriSema adds semaglutide in a sponsor FDC construct.
What did REDEFINE 1 show?
Under the trial product estimand at 68 weeks, CagriSema achieved −22.7% mean weight change vs −11.8% cagrilintide, −16.1% semaglutide, and −2.3% placebo (n≈3417; flexible protocol; 57.3% on highest CagriSema dose). Treatment policy estimand: −20.4% [REDEFINE 1 CA 99/2024].
What is REDEFINE 9’s public topline?
CagriSema 1.0/1.0 vs placebo at week 68: −21.0% vs −2.0% mean weight change (superiority). Full 1.7/1.7 and ≥5% responder tables were not in the open press used here [CMD 2026-09-21].
What did REIMAGINE 5 show vs tirzepatide?
At week 60, CagriSema 1.0/1.0 vs tirzepatide 5 mg: weight −12.4% vs −9.1% (superior); HbA1c −1.71% vs −1.67% (non-inferior) [CMD 2026-09-21].
Is CagriSema FDA-approved?
As of Q3 2026 sponsor materials, Novo described preparation for a possible early-2027 U.S. launch subject to regulatory approval, with an obesity-path FDA decision expected in Q4 2026 after a December 2025 NDA filing — that is pending review language, not a confirmed approved label on this page [Novo Q3 2026; Q3 2026 presentation PDF].
How does CagriSema differ from zenagamtide?
Zenagamtide is a single dual GLP-1/amylin peptide. CagriSema is a two-drug FDC of cagrilintide + semaglutide [zenagamtide hub].
How does it differ from EloraTZP?
EloraTZP pairs eloralintide with tirzepatide (amylin + GIP/GLP-1). CagriSema pairs cagrilintide with semaglutide (amylin + GLP-1) [EloraTZP hub].
How does it differ from retatrutide?
Retatrutide is a unimolecular GIP/GLP-1/glucagon triple agonist. CagriSema does not claim glucagon agonism as its third pathway [retatrutide hub].
Does SaiyanMed sell CagriSema?
No combo SKU is claimed on this page. For mono-amylin RUO reference material see cagrilintide product. This hub is research education only.
Can I use these trial percentages as a personal protocol?
No. Trial figures are published research / IR data under specific protocols. This page provides no dosing, reconstitution, or titration guidance.
Key takeaways
- CagriSema = Novo investigational cagrilintide + semaglutide fixed-dose combination (amylin + GLP-1) — educational map only; no SaiyanMed combo stock claim.
- REDEFINE 1 (68 wk, n≈3417): trial product estimand weight change −22.7% vs components and placebo; treatment policy −20.4% [REDEFINE 1 CA 99/2024].
- REDEFINE 9: CagriSema 1.0/1.0 −21.0% vs placebo −2.0% at 68 weeks (topline) [CMD 2026-09-21].
- REIMAGINE 1–3 (ADA 2026): consistent HbA1c and weight signals across T2D stages; see tables above [Novo US ADA 2026].
- REIMAGINE 5: only cite the published 1.0/1.0 vs tirzepatide 5 mg H2H (12.4% vs 9.1% weight; NI HbA1c) [CMD 2026-09-21].
- Architecture peers: zenagamtide = unimolecular; EloraTZP = different amylin + tirzepatide pairing; retatrutide = different third pathway.
- Q3 2026: sponsor preparing early-2027 U.S. launch subject to approval [Novo Q3 2026].
Related reading & research inquiry
- Cagrilintide hub
- Cagrilintide RUO product
- Eloralintide vs Cagrilintide
- What Is Zenagamtide (Amycretin)?
- What Is EloraTZP?
- What Is Retatrutide?
CTA (SKU-gated): If your laboratory needs verified mono-amylin reference material, see the cagrilintide product page. We will not invent a CagriSema combination inventory listing on this page. Notify-if-stock for any future combo-related listing requires supplier COA review and explicit go-ahead.
Research Use Only disclaimer
Research Use Only. Content summarizes published molecular, clinical-development, and company IR information for laboratory professionals. It does not provide medical or veterinary advice, validated experimental protocols, dosing or reconstitution instructions, or authorization for in-vivo work. Animal research requires applicable institutional approvals. CagriSema remains an investigational combination candidate unless and until a regulator issues an approved label — and even then, approved product labels are not RUO protocols. Semaglutide-containing approved products have their own labeled indications and safety information; this article is not a substitute for those labels and is not a use guide for approved medicines or for RUO materials.
Sources & further reading
- 1. Novo Nordisk — CagriSema REDEFINE 1 company announcement No 99 / 2024 (PDF resource) — https://ml-eu.globenewswire.com/Resource/Download/7c3d19b8-3501-4dcf-b698-33a21f73cbbe
- 2. GlobeNewswire HTML mirror (REDEFINE 1) — https://www.globenewswire.com/news-release/2024/12/20/3000444/0/en/novo-nordisk-a-s-cagrisema-demonstrates-superior-weight-loss-in-adults-with-obesity-or-overweight-in-the-redefine-1-trial.html
- 3. ClinicalTrials.gov NCT05567796 (REDEFINE 1) — https://clinicaltrials.gov/study/NCT05567796
- 4. NEJM REDEFINE 1 DOI (full text not fetched) — https://doi.org/10.1056/nejmoa2502081
- 5. Novo Nordisk — REIMAGINE 2 headline (2026-02-02, news-details id=916481) — https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916481
- 6. Novo Nordisk U.S. — CagriSema REIMAGINE Phase 3 T2D data at ADA 2026 (2026-06-07) — https://www.novonordisk-us.com/media/press-releases/cagrisema-phase3-reimagine-t2d-ada-2026.html
- 7. Novo / Via Ritzau — REIMAGINE 5 / REDEFINE 9 CMD topline (2026-09-21) — https://via.ritzau.dk/pressemeddelelse/15174087/novo-nordisk-as?publisherId=90446&lang=en
- 8. ClinicalTrials.gov NCT06534411 (REIMAGINE 5) — https://clinicaltrials.gov/study/NCT06534411
- 9. Novo Nordisk Q3 2026 company announcement (2026-11-04) — https://www.globenewswire.com/news-release/2026/11/04/3395015/0/en/novo-raises-full-year-outlook-on-continued-glp-1-momentum-with-third-quarter-adjusted-operating-profit-increasing-27-at-cer-to-dkk-31-720-million.html
- 10. Novo Nordisk Q3 2026 investor presentation PDF — https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/financial-results/2026/Q3-2026-Full-presentation.pdf
- 11. SaiyanMed — https://saiyanmed.com/cagrilintide/ · https://saiyanmed.com/product/cagrilintide/ · https://saiyanmed.com/eloralintide-vs-cagrilintide/ · https://saiyanmed.com/what-is-zenagamtide/ · https://saiyanmed.com/what-is-eloratzp/ · https://saiyanmed.com/what-is-retatrutide/